Impact of surgical margins on local control in patients undergoing single‐modality transoral robotic surgery for HPV‐related oropharyngeal squamous cell carcinoma

Head & Neck ◽  
2021 ◽  
Author(s):  
Andrew J. Holcomb ◽  
Matthew Herberg ◽  
Madeleine Strohl ◽  
Edgar Ochoa ◽  
Allen L. Feng ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Robotic Surgery ◽  
Cell Carcinoma ◽  
Local Control ◽  
Squamous Cell ◽  
Transoral Robotic Surgery ◽  
Oropharyngeal Squamous Cell Carcinoma ◽  
Surgical Margins ◽  
Single Modality

Transoral robotic surgery for oropharyngeal squamous cell carcinoma in the era of human papillomavirus

Head & Neck ◽  
2017 ◽  
Vol 40 (4) ◽  
pp. 710-721 ◽  
Author(s):  
Omar Mahmoud ◽  
Kim Sung ◽  
Francisco J. Civantos ◽  
Giovanna R. Thomas ◽  
Michael A. Samuels
Keyword(s):  
Squamous Cell Carcinoma ◽  
Human Papillomavirus ◽  
Robotic Surgery ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Transoral Robotic Surgery ◽  
Oropharyngeal Squamous Cell Carcinoma

Patient Selection for Transoral Robotic Surgery (TORS) in Oropharyngeal Squamous Cell Carcinoma

2021 ◽  
Vol 30 (2) ◽  
pp. 117-130
Author(s):  
Paul M. Bunch ◽  
Hafiz S. Patwa ◽  
Ryan T. Hughes ◽  
Mercedes Porosnicu ◽  
Joshua D. Waltonen
Keyword(s):  
Squamous Cell Carcinoma ◽  
Robotic Surgery ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Patient Selection ◽  
Transoral Robotic Surgery ◽  
Oropharyngeal Squamous Cell Carcinoma ◽  
Selection For

Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma

2021 ◽  
Vol 114 (3) ◽  
pp. 180-181
Author(s):  
Tomonori Terada ◽  
Kota Kida ◽  
Nobuhiro Uwa ◽  
Toshimitsu Sugawa ◽  
Kenzo Tsuzuki ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Robotic Surgery ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Transoral Robotic Surgery ◽  
Oropharyngeal Squamous Cell Carcinoma

Randomized Trial of Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Long-Term Results of the ORATOR Trial

2022 ◽  
Author(s):  
Anthony C. Nichols ◽  
Julie Theurer ◽  
Eitan Prisman ◽  
Nancy Read ◽  
Eric Berthelet ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Robotic Surgery ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Transoral Robotic Surgery ◽  
Oropharyngeal Squamous Cell Carcinoma ◽  
Md Anderson ◽  
Anderson Dysphagia Inventory ◽  
Over Time

PURPOSE The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has risen rapidly, because of an epidemic of human papillomavirus infection. The optimal management of early-stage OPSCC with surgery or radiation continues to be a clinical controversy. Long-term randomized data comparing these paradigms are lacking. METHODS We randomly assigned patients with T1-T2, N0-2 (≤ 4 cm) OPSCC to radiotherapy (RT) (with chemotherapy if N1-2) versus transoral robotic surgery plus neck dissection (TORS + ND) (with or without adjuvant therapy). The primary end point was swallowing quality of life (QOL) at 1-year using the MD Anderson Dysphagia Inventory. Secondary end points included adverse events, other QOL outcomes, overall survival, and progression-free survival. All analyses were intention-to-treat. Herein, we present long-term outcomes from the trial. RESULTS Sixty-eight patients were randomly assigned (n = 34 per arm) between August 10, 2012, and June 9, 2017. Median follow-up was 45 months. Longitudinal MD Anderson Dysphagia Inventory analyses demonstrated statistical superiority of RT arm over time ( P = .049), although the differences beyond 1 year were of smaller magnitude than at the 1-year timepoint (year 2: 86.0 ± 13.5 in the RT arm v 84.8 ± 12.5 in the TORS + ND arm, P = .74; year 3: 88.9 ± 11.3 v 83.3 ± 13.9, P = .12). These differences did not meet the threshold to qualify as a clinically meaningful change at any timepoint. Certain differences in QOL concerns including more pain and dental concerns in the TORS + ND arm seen at 1 year resolved at 2 and 3 years; however, TORS patients started to use more nutritional supplements at 3 years ( P = .015). Dry mouth scores were higher in RT patients over time ( P = .041). CONCLUSION On longitudinal analysis, the swallowing QOL difference between primary RT and TORS + ND approaches persists but decreases over time. Patients with OPSCC should be informed about the pros and cons of both treatment options (ClinicalTrials.gov identifier: NCT01590355 ).

Sign in / Sign up

Export Citation Format

Share Document